BOSTON, May 28, 2025 -- Aktis Oncology, Inc., an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, today announced...
Embrex, now a part of Zoetis (NYSE: ZTS), a global animal health company, developed and launched the world’s first commercial in ovo vaccination device more than 20 years ago. Its Inovoject® System is considered to be the industry standard for in ovo technology, revolutionized automation in the hatchery. Pfizer’s animal health division acquired Embrex in 2007.
Website
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.